Draegerwerk 9M net sales rise, EBIT jumps on one-off gains

Overview

• Germany medical and safety tech firm's 9M net sales rose 4.7% to EUR 2.45 bln

• EBIT up nearly 50%, aided by one-off customs refunds

• Company maintains 2026 forecast for net sales growth of 2-6% and EBIT margin of 6-8%

Outlook

• Drägerwerk maintains 2026 forecast for net sales growth of 2.0-6.0% (net of currency effects)

• Company expects 2026 EBIT margin of 6.0-8.0%

Result Drivers

• CUSTOMS REFUNDS - Co said one-off effects from U.S. customs refunds contributed EUR 27.9 mln to EBIT, including EUR 20.1 mln in Q3

• SAFETY DIVISION GROWTH - Safety division order intake increased 13.1% (net of currency effects), with all regions and product areas contributing

• GERMANY DEMAND - Germany was the largest growth driver, with order intake up 15% in 9M and 59% in Q3, boosted by defense orders

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Draegerwerk AG & Co KGaA is €101.50, about 31.8% above its October 28 closing price of €77.00

• The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago

Reuters Recommended Reads

• Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption

• Oct 28 - GE Healthcare Q3 profit beats estimates on advanced imaging segment

• Oct 27 - Sweden's Alfa Laval Q3 sales rise on order intake

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)